Pricing Log in Create free account

Capricor Therapeutics, Inc. (CAPR) vs Crescent Biopharma, Inc. (CBIO)

Capricor Therapeutics, Inc. and Crescent Biopharma, Inc. are both Biotechnology companies. Capricor Therapeutics, Inc. and Crescent Biopharma, Inc. are of similar size ($500.0M and $480.6M). Capricor Therapeutics, Inc. grew revenue faster over the last twelve months: −11.6% against −45.1%. Across the 14 metrics below, Capricor Therapeutics, Inc. leads on 9 and Crescent Biopharma, Inc. on 5.

Valuation

Metric CAPR CBIO Biotechnology median
P/E n/m n/m 10.60
P/S 23.51 337.85 9.40
P/B 2.13 2.58 2.13
Price to free cash flow 4.00 n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 13.47 227.76 9.02
Earnings yield (27.10%) (49.85%) (32.88%)
Free cash flow yield 25.00% (17.46%) (23.13%)

Profitability

Metric CAPR CBIO Biotechnology median
Gross margin 100.00% 19.72% 68.51%
Operating margin 0.00% 0.00% 0.00%
Net margin 0.00% 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity (73.70%) (101.95%) (51.96%)
Return on assets (51.53%) (88.26%) (46.06%)
Return on invested capital (1,019.73%) 0.00% 0.00%

Growth

Metric CAPR CBIO Biotechnology median
Revenue growth (TTM) (11.55%) (45.09%) 6.76%
EPS growth (last fiscal year) (96.52%) 78.20% 29.88%
Revenue growth, 5-year CAGR 85.83% 257.77% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CAPR CBIO Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 7.35 9.66 4.97
Net debt to EBITDA 2.99 1.40 1.01

Dividend

Metric CAPR CBIO Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric CAPR CBIO Biotechnology median
Market cap 500.00m 480.64m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack